Aids Weekly Plus
In 2011 private philanthropists in the US and the European Union spent approximately US $644 million on global HIV/AIDS programs, which was a 5 percent increase from 2010. The growth can be attributed to a few large donors, as several other donors had actually reduced their funding. The US-based Funders Concerned about AIDS (FCAA) and the European HIV/AIDS Funders Group (EFG) stated in their annual report that US funders spent $491 million in 2011, and EU funders spent $170 million. Sarah Hamilton of the FCAA pointed out that the Bill and Melinda Gates Foundation and a few others are the main funders behind the growth. If those funders are removed, there would be an overall decrease in private philanthropy for HIV/AIDS. “We look at it as level growth; we’ve identified a few new funders, but the growth is mild,” declared Hamilton.
An estimated 44 percent of US funding was aimed at programs with a global focus. US funding gave $69 million to East and Southern Africa, the most of any region outside the US, followed by the $40 million given to South Asia and the Pacific, and the $22 million given to East and Southeast Asia. Approximately half of all EU funding in 2011 was aimed at projects in regions and countries outside Western and Central Europe, and one third went to programs with a global aim. The EU spent 12 percent of its funding in Western and Central Europe. A large part of the US funding was directed toward research, with the top population groups being medical research teams and projects aimed at women, men who have sex with men, and youth. The EU funders mainly targeted women, vulnerable children, orphans, and youth
The report’s authors note that 2012 funding is forecasted to remain level. Experts are calling for greater funding, not only from the private funders but also from western governments and beneficiary nations. Paul De Lay, Deputy Executive Director for Programs at UNAIDS, noted “We are in an era where shared responsibility for the AIDS response is vitally important. Countries are stepping up their domestic investments for HIV, but there is still a $7 billion gap between what is needed and what is available.”